1-6 of 6
J. Elizabeth Pease, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Free
William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R. Patel, MD, Jay Yang, MD, Alireza Eghtedar, MD, Gautam M. Borthakur, MD, Julie Charlton, PhD, Alexander MacDonald, MSc-PhD, Anna Korzeniowska, MD, Elizabeth Sainsbury, BSc, Donald K. Strickland, MD, Suzanne Jones, PharmD, Philip Overend, MSc, Carrie A. Adelman, PhD, Giulia Fabbri, MD PhD, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Jan Cosaert, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3919.
https://doi.org/10.1182/blood-2019-130635
Published: 2019
Journal Articles

Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML

Free
Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, MD PhD, J. Elizabeth Pease, PhD, Giovanna Pomilio, Veronique Litalien, Jon Travers, PhD, Andrew H. Wei
Journal: Blood
Blood (2019) 134 (Supplement_1): 3930.
https://doi.org/10.1182/blood-2019-129564
Published: 2019
Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

Free
William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4064.
https://doi.org/10.1182/blood-2018-99-118465
Published: 2018
Journal Articles

Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models

Free
Wolfram Brugger, MD, Maureen Hattersley, PhD, Alexandra Bussey, PhD, Corinne Reimer, PhD, Adriana E. Tron, PhD, Anna Staniszewska, PhD, Oona Delpuech, PhD, Larissa Carnevalli, PhD, Cecile M. Krejsa, PhD, Michele Mayo, PhD, Lynne Neveras, PhD, Maryann San Martin, PhD, Abla Rideout, PhD, Theresa Proia, PhD, Brandon Willis, PhD, J. Elizabeth Pease, PhD, Ahmed Hamdy, MD, Sabina C. Cosulich, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4113.
https://doi.org/10.1182/blood.V130.Suppl_1.4113.4113
Published: 2017
Journal Articles

Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor

Free
Wolfram Brugger, MDPhD, Susan Ashton, Carrie A. Adelman, Nicolas Floc'h, Paula Taylor, Maureen Hattersley, PhD, Shenghua Wen, Kimberly Maratea, Philip Overend, Steven Fox, Julie Charlton, Simon T Barry, Donald Strickland, MD, Suzanne Jones, PharmD, Howard A. Burris, MD, Carol Greenlees, Alexander MacDonald, J. Elizabeth Pease, PhD, William Donnellan
Journal: Blood
Blood (2017) 130 (Supplement 1): 1368.
https://doi.org/10.1182/blood.V130.Suppl_1.1368.1368
Published: 2017
Journal Articles

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Free
Kristen A McEachern, PhD, Adriana E Tron, PhD, Greg O'Connor, Rachel DuPont, Francis D Gibbons, PhD, Lourdes Pablo, Karthick Vishwanathan, PhD, Patricia McCoon, PhD, Jorge E. Cortes, MD, Daniel J. DeAngelo, MDPhD, Mark D Minden, MDPhD, Geoffrey L. Uy, MD, Frank Neumann, MDPhD, Karen Keating, Dennis Huszar, PhD, J. Elizabeth Pease, PhD, Jeffrey Brown, PhD, J. Carl Barrett, PhD
Journal: Blood
Blood (2014) 124 (21): 906.
https://doi.org/10.1182/blood.V124.21.906.906
Published: 2014